This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    a study to evaluate characteristics predictive of a positive imaging study for distant metastases in
Previous Study | Return to List | Next Study

A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer (PREDICT)

This study is currently recruiting participants.
See Contacts and Locations
Verified January 2017 by Dendreon
Sponsor:
Information provided by (Responsible Party):
Dendreon
ClinicalTrials.gov Identifier:
NCT01981109
First received: October 28, 2013
Last updated: January 9, 2017
Last verified: January 2017
  Purpose
The primary purpose of this research is to describe patient characteristics predictive of an imaging study positive for distant metastases in patients with castration-resistant prostate cancer and no known distant metastases.

Condition
Castration-Resistant Prostate Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer

Resource links provided by NLM:


Further study details as provided by Dendreon:

Primary Outcome Measures:
  • Characteristics in patients with Castration-Resistant Prostate Cancer and no known M1. [ Time Frame: Up until 5 years after the last patient is registered ]
    To evaluate characteristics predictive of a baseline imaging study positive for M1 in patients with Castration-Resistant Prostate Cancer and no known M1.


Secondary Outcome Measures:
  • The sites of distant metastases [ Time Frame: Within the 2 year enrollment period ]
    To characterize the sites of distant metastases by determining the proportion of patients with Castration-Resistant Prostate Cancer and no known M1 who receive a diagnosis of soft tissue and/or bone metastases at the time of the baseline imaging study.

  • Characteristics in patients with Castration-Resistant Prostate Cancer and no distant metastases at baseline. [ Time Frame: Up until 3 years after the last patient is registered ]
    To evaluate characteristics predictive of a future imaging study positive for M1 in patients with Castration-Resistant Prostate Cancer and no distant metastases at baseline.


Biospecimen Retention:   Samples With DNA
Whole blood, serum

Estimated Enrollment: 2000
Study Start Date: January 2012
Estimated Study Completion Date: January 2022
Estimated Primary Completion Date: January 2022 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Men with Castration-Resistant Prostate Cancerand no known M1 disease who are at least 18 years of age at the time of screening are eligible.
Criteria

Inclusion Criteria:

  • Written informed consent obtained prior to the initiation of study procedures.
  • Men ≥ 18 years of age.
  • Histologically documented prostatic adenocarcinoma.
  • History of Castration-Resistant Prostate Cancer.

Exclusion Criteria:

  • Known M1 disease.
  • Undergone imaging study for metastatic prostate cancer ≤ 3 months.
  • ECOG performance status ≥ 3.
  • Known malignant pleural effusions or ascites.
  • Current or prior treatment with investigational therapy for M0 Castration-Resistant Prostate Cancer (Taxotere (docetaxel), Provenge® (sipuleucel-T), Zytiga (abiraterone acetate), Xtandi (enzalutamide), Jevtana (cabazitaxel), or Xofigo (radium Ra 223 dichloride).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01981109

Contacts
Contact: Sally Anne Jones Sallyanne.Jones@dendreon.com
Contact: Evett Oh 949-436-9104 eoh@dendreon.com

  Show 61 Study Locations
Sponsors and Collaborators
Dendreon
Investigators
Study Director: Robert Israel, MD Valeant Pharmaceuticals North America LLC
  More Information

Responsible Party: Dendreon
ClinicalTrials.gov Identifier: NCT01981109     History of Changes
Other Study ID Numbers: P12-1
Study First Received: October 28, 2013
Last Updated: January 9, 2017

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on June 22, 2017